Florian Schindler

We are very excited to say that after more than 30 years of research and development, we have received the Swissmedic approval for our new treatment for resistant hypertension in our home country of Switzerland, following the approval in the US and EU last year and the UK earlier this year. We are engaged in discussions with potential partners to make this drug available to patients across Switzerland and Europe. Read more: https://bit.ly/idiamr

723

4 Kommentare

📢 This week marks a promising milestone in our journey at XVIVO: the first patient has been enrolled in the Continued Access Protocol (CAP) study for our XVIVO Heart Assist Transport technology in the United States.   At its core, the CAP represents continuity, patient access, regulatory partnership and hope. The CAP ensures that transplant teams can continue to use the XVIVO Heart Assist Transport, without interruption, as we analyze one-year follow-up data from our clinical trial.   What this means in practice: 🔹 Up to 60 additional patients at 26 transplant centers will enroll. 🔹 This CAP study follows the successful PRESERVE Trial. The protocol closely mirrors that of the original IDE study, ensuring continuity in safety and efficacy data collection. 🔹 Due to CMS reimbursement approval, hospitals and patients will have access to this lifesaving technology. 🔹 Patients awaiting heart transplants can continue to benefit from XVIVO’s heart technology, even as we complete the final steps toward gaining Pre-Market Approval. 🔹 Transplant teams ensure continuity of care while the technology’s safety and efficacy continue to be formally reviewed.   For patients and families waiting for a second chance, this approval matters 💙 Nobody should die waiting for a new organ. Grateful to everyone across our team, transplant centers, partner organizations, and the FDA which make it possible to provide lifesaving care to people in need.   📄 Read more about how this will impact lives in our press release here: https://lnkd.in/dD6uc4Wn #HeartTransplant #MedicalInnovation #PatientAccess #HealthTech #LifeSavingTechnology #ClinicalTrial  

308

8 Kommentare

🔬 It started with a vision — and a yellow legal pad. Over 40 years ago, Dr. Tom Grogan set out to transform cancer diagnostics. Frustrated by the slow, manual lab processes of the time and knowing the potential for synergies between diagnostics and targeted therapies, he saw the possibility to deliver faster, more accurate answers for patients. Watch Dr. Grogan’s interview and read more about the evolution of pathology and Roche Tissue Diagnostics: go.roche.com/li-VENTANA-40

426

3 Kommentare

Ypsomed Holding AG (SIX: YPSN) announced that the sale of the Ypsomed Diabetes Care business to TecMed AG, initially announced on 22 April 2025, has now been completed. This is a strategic milestone for Ypsomed as it refocuses on its market-leading position in subcutaneous self-injection solutions for pharmaceutical and biotech companies.   Walder Wyss advised Ypsomed on the carve-out of the diabetes care business and the sale to TecMed AG. The team was led by Hans-Jakob Diem (Partner, Corporate/M&A) and Dominik Hohler (Partner, Corporate/M&A) and included Letizia Schlegel (Senior Associate, Corporate/M&A), Michael Kissling (Senior Associate, Corporate/M&A), Michael Isler (Partner, IP/Data Protection and Regulatory), Kento Reutimann (Associate, IP/Data Protection), Florian Iten (Associate, Corporate/M&A), Valentin Wiesner (Managing Associate, Finance) and Valentin Freiermuth (Associate, Finance). https://lnkd.in/dg9_VQ-S

56

We are proud to introduce 𝗣𝗨𝗟𝗦𝗘 — the Portable Ultra-Low-Field Scientific Exchange. PULSE is a platform that unlocks access to innovative Hyperfine technology and creates a community for researchers and developers around the world, empowering them to accelerate innovation in portable MRI technology. PULSE gives clinical researchers and developers unprecedented access to advanced tools enabling the community to: • Leverage proprietary Hyperfine research sequences, powered by Optive AI™ software • Import and adapt community-developed sequences • Access raw data “We look forward to partnering with and supporting the global community of PULSE subscribers so that together, we can unlock the revolutionary potential of portable MRI." –Maria Sainz, Hyperfine President and CEO Learn more here: https://lnkd.in/gVydhuuT #MedTech #AIinHealthcare #MRICommunity

63

👋 Welcome to Biopôle, Undae Science SA! 💤 Built on deep sleep expertise, Undae Science is working to transform clinical sleep management and improve population health. Sleep disturbances already cost Switzerland over CHF 10 billion each year, and current diagnostics rely on intrusive, single-night hospital exams that often disrupt natural sleep and delay accurate diagnoses. 💡 Their innovation, Noctae, reimagines the sleep medical station: a user-friendly, contactless over-mattress device that enables multi-night, clinical-grade monitoring in the comfort of home. Powered by proprietary AI and years of cutting-edge research, Noctae delivers accuracy on par with hospital gold standards without the need for overnight stays. 🔎 Learn more about their pioneering approach to sleep health: https://lnkd.in/dAKwmktb

147

4 Kommentare

🚀 Startup of the Week | Berlin Heals Holding AG This week, meet Berlin Heals, a Swiss-German MedTech company pioneering heart failure treatment through its proprietary Cardiac Microcurrent Therapy (C-MIC). ❌ Heart failure impacts over 60M people worldwide, remaining a leading cause of hospitalization. ✅ Berlin Heals’ C-MIC device delivers targeted electrical microcurrents to restore heart function — offering new hope for patients. 💡 With the first-in-human implant completed in 2019 and clinical studies underway across Europe and the US, they are rapidly moving toward CE marking and global introduction. 💰 Recently, they also closed a $5M funding round to expand their less invasive work — a key milestone in their growth journey. Read more about it here: https://lnkd.in/g7YEnRfz 🌍 Berlin Heals will showcase their innovation at MedTech Malta 2025, joining global investors, regulators, and leaders in healthcare. 📣 Are you building the next breakthrough in healthcare? Pitch at our upcoming events and share your vision with the world. 👉🏻 https://lnkd.in/e6snG5SA 🗓️ MedTech World Singapore — 01 October 🎟️ Pre-reg Now: https://lnkd.in/duBF8jVT 🗓️ MedTech Malta — 12–14 November | Malta 🎟️ Tickets: https://lnkd.in/gYcvJ6F8 #StartupOfTheWeek #BerlinHeals #MedTech #MedTechMalta #HealthTech #HealthcareInnovation

56

2 Kommentare

Quality meets Expertise 2025 | Cardiovascular Diseases 🌍   From Monday, July 28 to Friday, August 1, our latest Quality meets Expertise event took place in Berlin, bringing together healthcare professionals to foster networking and encourage knowledge exchange in the field of cardiovascular diseases.   We were honored to have two keynote speakers:   Univ.-Prof. Dr. Donato Santovito from LMU Klinikum München presented on cardiovascular prevention and patient-tailored therapies, focusing on strategies to manage cardiovascular risk factors effectively.   Dr. Moez J. Mobarek from the Al-Jawad Oncology Center in Baghdad examined the prevention and treatment of cancer-associated thrombosis, emphasizing the importance of preventive measures and providing guidance on the administration of apixaban for Venous Thromboembolism (VTE).   Watch the full Aftermovie on YouTube: https://lnkd.in/dXYBMdmj    #QualityMeetsExpertise #CardiovascularHealth #HealthcareInnovation #Berlin

74

2 Kommentare

Great news from our subsidiary, cecava GmbH: Precision Medicine Online, an established news and analysis portal for precision oncology, has published an in-depth article based on an interview with Saskia Biskup, MD/PhD. It covers the latest developments in individualized peptide therapy for IDH1-mutated gliomas. Based on cecava's recent press release, the article highlights the scientific background, key study results, and the next steps toward a clinical trial. We are delighted about this well-deserved attention and congratulate the entire cecava team! Learn more about cecava's pioneering approach here: https://lnkd.in/eAtAAKVu Read the full article on Precision Medicine Online here (subscription needed): https://lnkd.in/eGuKt4cX

84

2 Kommentare